Trial Profile

A Phase 2 study of HTL0048149

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HTL 0048149 (Primary)
Indications Schizophrenia
Focus Adverse reactions
Sponsors Nxera Pharma

Most Recent Events

01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
13 Mar 2024 New trial record
11 Mar 2024 According to Sosei Heptares media release, company will receive an upfront payment of 25 million from Boehringer Ingelheim upon signing, and is eligible for an option exercise payment of 60 million and further development, regulatory and commercialization milestone payments totaling up to EUR 670 million plus customary tiered royalties

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com